Although immune checkpoint blocking monoclonal antibodies such as PD-1, PD-L1 and CTLA-4 have shown significant prospects in some cancers, the treatment response of ovarian cancer still remains unsatisfied [5, 6]. The gene discussed is PDCD1; the disease is ovarian carcinoma.